Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA DEVICE REFORM BILL'S "SCOPE OF REVIEW" CONTROVERSY CAN BE ADDRESSED IN CONFERENCE, SEN. JEFFORDS SAYS; FLOOR VOTE ON PROVISION SLATED FOR SEPT. 23

This article was originally published in The Gray Sheet

Executive Summary

The controversy over the 510(k) "scope of review" provision in the Senate FDA reform/Prescription Drug User Fee Act reauthorization bill (S 830) can be resolved in House-Senate conference and should not delay a vote on the measure, Senate Labor and Human Resources Committee Chairman James Jeffords (R-Vt.) said Sept. 19 during floor debate on the bill.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel